RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients

A Chakravarti, M Wang, HI Robins… - International Journal of …, 2013 - Elsevier
PURPOSE: To determine the safety and efficacy of gefitinib, an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation for newly diagnosed …
被引用次数：175 相关文章

RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

A Chakravarti, M Wang, HI Robins… - International Journal of …, 2013 - redjournal.org
Purpose To determine the safety and efficacy of gefitinib, an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation for newly diagnosed …

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.

A Chakravarti, M Wang, HI Robins… - … Journal of Radiation …, 2012 - europepmc.org
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly
diagnosed glioblastoma patients. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
[PDF] academia.edu

[PDF][PDF] RTOG 0211: A Phase I/II Study of Radiation Therapy with Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

P Dicker11, M Bredel12, M Mehta13 - Int J Radiat Oncol Biol Phys, 2013 - academia.edu
NIH Public Access Page 1 RTOG 0211: A Phase I/II Study of Radiation Therapy with Concurrent
Gefitinib for Newly Diagnosed Glioblastoma Patients Arnab Chakravarti1, Meihua Wang2, H …
[PDF] researchgate.net

[PDF][PDF] RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

E Meyers, N Merck, S Novocure - Int J Radiation Oncol Biol Phys, 2013 - researchgate.net
The addition of gefitinib to radiation therapy (RT) does not appear to improve outcome in the
general population of newly diagnosed glioblastoma (GBM) patients. Epidermal growth …

RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

A Chakravarti, M Wang, HI Robins… - International Journal of …, 2013 - osti.gov
Purpose: To determine the safety and efficacy of gefitinib, an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation for newly diagnosed …

RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

A Chakravarti, M Wang, HI Robins… - International Journal of …, 2013 - inis.iaea.org
[en] Purpose: To determine the safety and efficacy of gefitinib, an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation for newly diagnosed …

[引用][C] RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.

A Chakravarti, M Wang… - International …, 2013 - baptisthealth.elsevierpure.com
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed
glioblastoma patients. — Baptist Health South Florida's Research Portal Skip to main navigation …

RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients

A Chakravarti, M Wang, HI Robins… - International …, 2013 - ohiostate.elsevierpure.com
Purpose: To determine the safety and efficacy of gefitinib, an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation for newly diagnosed …
[HTML] nih.gov

[HTML][HTML] RTOG 0211: A Phase I/II Study of Radiation Therapy with Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

A Chakravarti, M Wang, HI Robins… - … journal of radiation …, 2013 - ncbi.nlm.nih.gov
RTOG 0211: A Phase I/II Study of Radiation Therapy with Concurrent Gefitinib for Newly
Diagnosed Glioblastoma Patients - PMC Back to Top Skip to main content NIH NLM Logo …